Home > Boards > US Listed > Biotechs > MediciNova, Inc. (MNOV)

A thought from my friend Carl:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Minding Member Profile
 
Followed By 15
Posts 830
Boards Moderated 0
Alias Born 03/03/10
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/21/2019 12:13:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:07:04 PM
MediciNova to Present at the JMP Securities Life Sciences Conference GlobeNewswire Inc. - 6/12/2019 7:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:15:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:05:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:03:53 PM
MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS GlobeNewswire Inc. - 6/5/2019 7:00:00 PM
MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference GlobeNewswire Inc. - 5/15/2019 7:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 4:42:49 PM
MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the ... GlobeNewswire Inc. - 5/7/2019 7:00:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/1/2019 5:29:15 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 5:10:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/26/2019 6:22:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 4:33:49 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/25/2019 4:20:32 PM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlobeNewswire Inc. - 4/23/2019 7:00:00 PM
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS GlobeNewswire Inc. - 4/15/2019 7:00:00 PM
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholes... GlobeNewswire Inc. - 4/3/2019 7:00:00 PM
MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire Inc. - 4/1/2019 7:00:00 PM
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multi... GlobeNewswire Inc. - 3/24/2019 7:00:00 PM
MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan GlobeNewswire Inc. - 3/5/2019 6:51:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2019 6:12:08 AM
MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientif... GlobeNewswire Inc. - 2/28/2019 6:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2019 6:44:27 AM
Minding   Thursday, 11/19/15 03:42:06 PM
Re: None
Post # of 392 
A thought from my friend Carl:

MNOV is attempting to treat just about everything with its drugs. I have never seen any company of this size with so many irons in the fire. And they have been able to fund their trials with external sources of money.

MNOV's chart is improving. However it will take news that confirms that their drugs work in one of these research projects for a big move to take place. The market cap is about $97m so there is plenty of possible room to the upside if good news is revealed.

Kind regards,
Minding

-----------------

MediciNova initiates mid-stage study of MN-001 for elevated triglycerides in NASH patients

Nov 19 2015, 12:05 ET | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
MediciNova (MNOV -1.9%) initiates a Phase 2a clinical trial assessing MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH (nonalcoholic steatohepatitis) patients. The open-label, multicenter, proof-of-concept study will enroll ~20 participants. Eligible patients will have a confirmed diagnosis of NASH and serum triglyceride levels of at least 150 mg/dL (normal level is less than 150 mg/dL). Each subject will receive 250 mg of MN-001 once per day for four weeks followed by 250 mg twice per day for eight weeks.

MN-001 is under development for the treatment of NASH with fibrosis and ideopathic pulmonary fibrosis.

Tipelukast is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase.

Previously: MediciNova's tipelukast Fast Track'd for ideopathic pulmonary fibrosis; shares up 17% premarket (Sept. 10)

Previously: MediciNova jumps on FDA OK of second Phase 2 protocol for MN-001 in NASH (July 27)



MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan

MNOV: Presentation on ALS Phase 2 Study in December?

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis


MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist